Formulation and evaluation of irbesartan nanosuspension for dissolution enhancement

Mistry Khushboo, Kavya Naik, Vasanthi, Alicia Menezes, Anup Naha, K. B. Koteshwara, K. Girish Pai

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Irbesartan, an angiotensin receptor blocker, a BCS class II drug is effective in lowering blood pressure but is having low aqueous solubility and low bioavailability. Hence, the present study was aimed to prepare and evaluate nanosuspension of Irbesartan for enhancement of dissolution. Preformulation studies like, DSC, FTIR was performed to evaluate the drug excipient compatibility. A full factorial method was utilized to study the effect of various factors such as surfactant concentration, sonication amplitude and sonication time on Irbesartan nanosuspension in two levels using Design Expert 10 software. In vitro drug release of optimized and pure drug was performed in pH 1.2 and pH 6.8 buffers. FT-IR and DSC studies showed no interaction between the drug and the excipients. Optimized nanosuspension showed particle size (149.639 nm), PDI (0.195) and zeta potential (-5.639). The nanoparticle formulation showed a prolonged improved drug release for 24 hours in phosphate buffer pH 6.8 (89.09%) as compared to pure drug dispersion (67.69%)

Original languageEnglish
Pages (from-to)3043-3048
Number of pages6
JournalResearch Journal of Pharmacy and Technology
Issue number9
Publication statusPublished - 01-09-2017

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Pharmacology (medical)


Dive into the research topics of 'Formulation and evaluation of irbesartan nanosuspension for dissolution enhancement'. Together they form a unique fingerprint.

Cite this